Adipotide: The Fat-Vessel Killer That Stalled in Humans
Adipotide melts white fat by destroying the blood vessels feeding it. Striking animal data, zero human efficacy evidence, and kidney toxicity that ended its development.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-15A reproducible animal weight-loss signal against a validated human target, but no validated human benefit: clinical development was discontinued over dose-limiting kidney toxicity, the therapeutic window is narrow, and preclinical findings do not establish human benefit.
Coherent ligand-directed apoptosis mechanism; the prohibitin target was confirmed on human white-fat vasculature.
Consistent fat ablation and weight loss in obese mice and Old World monkeys, objectively confirmed by MRI/DEXA.
A first-in-human Phase 1 trial ran but was terminated with no published efficacy or safety results.
No validated human benefit; the effect also appears reversible after stopping.
Animal data flag dose-dependent renal proximal-tubule injury; human safety is essentially uncharacterised in the literature.
Reached Phase 1, then development was discontinued; only successor molecules remain in preclinical work.
A strong animal signal but a failed/abandoned human translation keeps confidence low.
Unapproved, development discontinued over toxicity; grey-market 'research' supply is sold for weight loss to non-clinical users.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A fat-vasculature-ablating peptide with reproducible weight-loss signals in mice and monkeys, but no published human efficacy or safety results; the mechanism is plausible, not clinically validated.
Safety snapshot
Animal data flag dose-dependent kidney (renal proximal-tubule) injury and a narrow therapeutic window; the one first-in-human trial was terminated, and human safety is essentially uncharacterised.
Regulatory & legality
Unapproved everywhere; clinical development was discontinued, and the realistic supply is grey-market 'research' product.
Where claims can exceed the evidence
Preclinical findings do not establish human benefit; the effect also appeared reversible after stopping in animals.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Adipotide is one of the more dramatic ideas in obesity research: instead of curbing appetite or nudging metabolism, it kills the blood vessels that feed white fat, starving the fat depot until the body resorbs it. On paper it is elegant. In obese mice it reversed obesity [1]. In obese monkeys it produced roughly 11% body-weight loss in about four weeks alongside improved insulin sensitivity [2].
Here is the catch that matters most to anyone considering it: every benefit claim above comes from animals. Adipotide reached a first-in-human trial and then development was discontinued, widely attributed to dose-limiting kidney toxicity and a narrow therapeutic window [12]. There is no published human efficacy or safety data at all. The evidence base is genuinely emerging, and the human chapter never got written.
This article walks through what adipotide is, what the research actually shows, and why the gap between "spectacular in mice" and "abandoned in people" is the whole story.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
AOD-9604: The Fat-Loss Peptide That Failed Its Own Trial
AOD-9604 is a growth-hormone fragment with strong fat-loss data in animals — but its pivotal human obesity trial failed, and it was never approved as a medicine.
Cagrilintide: The Amylin Analogue Behind CagriSema
A plain-English, evidence-first look at cagrilintide — the long-acting amylin analogue, its trial record, doses studied, and why it is almost never used alone.
Mazdutide: The First GLP-1/Glucagon Dual Agonist, and What the Trials Actually Show
Mazdutide is a once-weekly GLP-1/glucagon dual agonist with strong phase 3 evidence (up to ~20% weight loss) — but it is China-only and largely untested elsewhere.
Retatrutide: The Triple Agonist Pushing Weight Loss Past Everything Before It
An evidence-first look at retatrutide, the investigational GLP-1/GIP/glucagon triple agonist posting the largest weight-loss numbers seen in any incretin trial to date.